Screening of Amodiaquine for its in vitro Anti-cancer Activity on Breast Cancer Cell Lines- a Case Study for Drug Reprofiling

Background: Cancer is one of the foremost contributors to global disease bur den and constantly requires new therapeutic options. The development drugs has failed keep up with its incidence. Hence, drug reprofiling strategies are emerging as novel study aimed evaluate anti-cancer activity amodiaquine (anti-malarial drug) using a combination murine human breast cancer cell lines Methods: Amodiaquine was authenticated by ultra-violet spectrophotometry, high- performance liquid chromatography 1D nuclear magnetic resonance. In vitro cytotoxicity evaluated against three lines. MDA-MB-453, 4T1 MDA-MB-231 cells were incubated at different concentrations (0.78, 1.56, 3.13, 6.25, 12.50, 25.00, 50.00, 100.00 ?M) for 72 h, after which viability testing conducted counting kit-8 assay. Negative control in no added also evaluated. flow cytometry analysis when treated cytometer annexin V/propidium iodide staining Results: Cell studies showed that IC50 values on 4T1, MDAMB-231 6.48 ± 1.12, 10.50 1.17, 19.23 1.16 ?M, respectively. death necrosis. Conclusion: This shown may be potentially reprofiled an agent managing androgen receptor-positive / HER-2 positive triple-negative types. An additional probable mechanism action found necrosis .